Friday, September 16, 2016

UPDATE 1-Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent

COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk's

experimental injectable diabetes drug semaglutide reduced

cardiovascular risk by 26 percent according to the keenly

awaited results of a clinical trial released on Friday.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)